Citations

Clear

13603 citation(s) found for "_, _".

Anticoagulation and Neuraxial Block: Historical Perspective, Anesthetic Implications, and Risk Management
Horlocker, Terese T. , Wedel, Denise J.

Mayo Clinic

Regional Anesthesia & Pain Medicine | October 11, 2025 | Volume: 23 | Issue: Suppl 2 | Pages: 129-134

10.1136/rapm-00115550-199823062-00001 Get It

Defining the Cross-sectional Anatomy Important to Interscalene Brachial Plexus Block with Magnetic Resonance Imaging
Wong, G Y, Brown, D L, Miller, G M, Cahill, D R, Wong, G Y, Brown, D L, Miller, G M, Cahill, D R

Mayo Clinic

Regional Anesthesia: The Journal of Neural Blockade in Obstetrics, Surgery, & Pain Control | October 11, 2025 | Volume: 21 | Issue: Suppl 2 | Pages: 20-20

10.1136/rapm-00115550-199621021-00020 Get It

Research experience, goals, and priorities of pediatric neurosurgeons: a survey of the American Society of Pediatric Neurosurgeons
Bristol, Ruth E., Durham, Susan, Hankinson, Todd C. , Kulkarni, Abhaya V. , Weiner, Howard L. , Weprin, Bradley E. , Wellons, John C. , Hersh, David S. , Daniels, David J. , Robinson, Shenandoah

Mayo Clinic

Journal of Neurosurgery: Pediatrics | October 11, 2025 | Volume: 36 | Issue: 6 | Pages: 779-788

10.3171/2025.6.peds25132 | PMID 41072039 Get It

OBJECTIVE Neurosurgeon scientists play a unique role in advancing neuroscience research. While previous publications have explored trends in federal and foundation funding among neurosurgeons, funding is often dominated by neurosurgical oncologists and functional neurosurgeons. Less is known about the research efforts of pediatric neurosurgeons. The aim of this study was to survey the members of the American Society of Pediatric Neurosurgeons (ASPN) to provide an overview of past research experience, current involvement, funding, and research priorities among pediatric neurosurgeons, and to gather insights that could shape future efforts to advance pediatric neurosurgical research. METHODS A survey was developed using the REDCap platform and distributed to all ASPN members via email. Survey questions used branching logic and were organized into 5 sections: 1) demographics, 2) research experience during training, 3) research experience as an attending physician, 4) research priorities, and 5) multicenter consortiums. RESULTS One hundred thirty-nine respondents completed more than half of the survey, for an overall response rate of 52.1%. Most respondents (96.4%) participated in research during their training, but only 38.1% had received a grant during training. In contrast, 83.9% of respondents were actively engaged in research as an attending physician, and 48.7% reported active funding (60.7% federal, 41.8% from foundations, and 42.9% internal). Furthermore, 74.8% of respondents reported being a member of a multicenter research consortium, and 82.4% agreed that multicenter research is important. Seventy percent of respondents agreed that the ASPN should facilitate multicenter consortium-based pediatric neurosurgical research, offering free-text responses with the following suggestions: 1) set aside time at the annual meeting to discuss multicenter research (22.9%); 2) encourage collaboration and facilitate networking (42.9%); 3) provide centralized core services such as a data coordinator and biostatistician (12.9%); and 4) provide training, education, and mentoring (7.1%). CONCLUSIONS The survey provided a cross-sectional analysis of the pediatric neurosurgical research landscape, highlighting the current state of research experience, funding, and the perspectives of pediatric neurosurgeons regarding research priorities. Despite the challenges, there is clear recognition of the importance of multicenter research collaboration. These findings reinforce the ongoing necessity of organized initiatives to support pediatric neurosurgical research and offer actionable insights into how organized pediatric neurosurgery can contribute to this critical endeavor.
Expert Practice Patterns for Screening, Diagnosis, and Management of Barrett’s Esophagus in the United States
Iyer, Prasad G. , Clarke, John O. , Kamal, A. N. , Wang, Fangfang, Kamal, Afrin N , Clarke, J , Wang, Fangfang, Kahn, Allon

Mayo Clinic

Journal of Clinical Gastroenterology | October 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/mcg.0000000000002259 | PMID 41071183 Get It

Goals: This study aimed to assess perspectives and practices among expert gastroenterologists regarding the screening, diagnosis, and management of BE. Background: Significant variability in the management of Barrett’s esophagus (BE) persists among physicians despite the development and dissemination of several clinical practice guidelines. Study: An online survey was conducted with 38 expert gastroenterologists specializing in BE management. The 38-question survey evaluated demographics, medical management, and attitudes toward endoscopic treatment, with responses analyzed for trends and variations. Results: Of the 38 experts, 34 (89%) responded. Respondents were primarily male (85%), with 82% affiliated with academic hospitals and 53% clinically focused on BE. Half discussed BE risks during initial consultations for gastroesophageal reflux disease (GERD). Most (61.8%) agreed BE should be considered in women with chronic GERD, and 88.2% regularly used narrow-band imaging (NBI). However, 44% were neutral or disagreed with diagnosing BE based solely on community gastroenterologist biopsies, and acceptance of Wide-Area Transepithelial Sampling with 3D Analysis (WATS-3D) for Barrett’s esophagus diagnosis and surveillance was limited. Fifty-three percent recommended ablation for nondysplastic BE. Fifty-two percent recommended indefinite daily PPI therapy after complete eradication of intestinal metaplasia (CEIM), regardless of symptoms. When encountering cardia intestinal metaplasia after endoscopic eradication, 38% recommended ablation, while 47% continued surveillance. Conclusion: This study highlights substantial variations in the management of BE among expert gastroenterologists, despite the existence of updated guidelines. Identifying these discrepancies is crucial for optimizing care. Further efforts are needed to standardize practices and enhance the implementation of evidence-based guidelines in clinical settings.
Protocols, Complications, and Outcomes of Pressurized Intraperitoneal Aerosol Chemotherapy for Patients With Peritoneal Metastasis: A Systematic Review of the Literature
Reynolds, Ian S. , Merchea, Amit , Mulsow, Jürgen , McKenna, Nicholas P , Reynolds, Ian S , Duggan, William P. , McKenna, Nicholas P.

Mayo Clinic

Journal of Surgical Oncology | October 10, 2025 | Volume: 132 | Issue: 7 | Pages: 1197-1209

10.1002/jso.70109 | PMID 41070715 Get It

ABSTRACT Background The use of pressurized intraperitoneal aerosol chemotherapy (PIPAC) is becoming more frequent for patients with unresectable peritoneal metastases. This systematic review explores the indications, protocols, feasibility, safety, oncological outcomes, patient reported outcomes and quality of life outcomes for patients being treated with PIPAC. Methods A review of PubMed, Embase and the Cochrane Library was undertaken to identify studies pertaining to patients undergoing treatment with PIPAC. Clinicopathological characteristics, treatment protocols, safety data, treatment response data and outcome data were extracted from relevant studies and included in the analysis. Results Data from 1980 patients undergoing 4454 PIPAC procedures for peritoneal metastases from a range of primary cancers was extracted. The treatment protocols identified were relatively homogenous across all studies. Grade 3/4 complications, grade 3/4 toxicity and procedure related mortality occurred infrequently. At least partial histological response was seen in 61.8% of patients. Overall survival for studies presenting data for mixed primary tumors ranged from 8 to 25 months. Quality of life and function were relatively stable throughout treatment. Conclusions PIPAC is a safe and feasible treatment option for patients with peritoneal metastases. Ongoing studies are required to evaluate how it compares to best option standard of care chemotherapy.
Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US Women
Keil, Alexander P. , Taylor, Jack A. , Yadav, Siddhartha , Culver, Hoda Anton, Auer, Paul L. , Bodelón, Clara , Haiman, Christopher A., Lindströem, Sara, Martinez, Maria Elena, Nathanson, Katherine L. , Patel, Alpa V. , Penney, Kathryn L., Ruddy, Kathryn J. , Teras, Lauren R., Vachon, Celine M. , Weitzel, Jeffrey N. , Yao, Song, Weitzel, Jeffrey N , Yadav, Siddhartha , Taylor, Jack A , Nathanson, Katherine L , O’Brien, Katie M. , Weinberg, Clarice R. , Polley, Eric C. , Boddicker, Nicholas , Hu, Chunling , Ambrosone, Christine B. , Brantley, Kristen D. , Burnside, Elizabeth S. , Chen, Fei , Domchek, Susan M. , Eliassen, A. Heather , Hodge, James M. , Kraft, Peter , Lacey, James V. , Neuhausen, Susan L. , Olson, Janet E. , Palmer, Julie R. , Penney, Kathryn , Scott, Christopher G. , Teras, Lauren R. , Trentham‐Dietz, Amy , Vachon, Celine M. , Yao, Song , Zirpoli, Gary , Couch, Fergus J. , Sandler, Dale P.

Mayo Clinic

JAMA Oncology | October 9, 2025 | Volume: 11 | Issue: 12 | Pages: 1458

10.1001/jamaoncol.2025.3875 | PMID 41066089 Get It

Importance Inherited pathogenic variants (PVs) in known predisposition genes can greatly increase breast cancer risk, but the combined impact of PV status, family history, and other factors on breast cancer risk in the general US population has not been well described. Objective To evaluate population-based breast cancer risk estimates for those with established PVs overall and stratified by first-degree family history of breast cancer and other factors. Design, Setting, and Participants This study used pooled data from 13 US-based breast cancer case-control studies participating in the Cancer Risk Estimates Related to Susceptibility (CARRIERS) consortium. Enrollment for individual studies occurred between 1976 and 2013, and results are based on data released March 2023, with analyses conducted from June 2022 to July 2025. Exposures PVs, breast cancer family history, self-reported race and ethnicity, and established risk factors. Main Outcomes and Measures Breast cancer rate ratios for PVs in 7 genes were estimated from the CARRIERS consortium. PV status and incidence and mortality statistics were combined using the Individualized Coherent Absolute Risk Estimation (iCARE) model to estimate conditional cumulative breast cancer risks and 95% CIs, stratified by family history and standardized to the US population. Models that incorporated population-based data and published estimates for established epidemiologic risk factors were also evaluated. Results A total of 67 692 women were studied, including 33 841 who were diagnosed with breast cancer. PVs in ATM , BRCA1 , BRCA2 , CHEK2 , and PALB2 were strongly associated with breast cancer risk, with BRCA1 and PALB2 PVs showing evidence of heterogeneity by family history. In models considering PVs, family history, and established risk factors, the estimated cumulative risks of breast cancer by age 50 years ranged from 2.4% (95% CI, 2.4-2.4) in women with no PVs and no family history to 35.5% (95% CI, 21.6-55.1) in PALB2 PV carriers with a family history. Among women who have not been diagnosed with breast cancer by age 50 years, the cumulative risk of breast cancer by age 80 years ranged from 11.1% (95% CI, 11.0-11.2) in noncarriers with no family history to 70.5% (95% CI, 52.8-83.5) for PALB2 carriers with a family history. PV-specific cumulative risk estimates varied across subgroups defined by race and ethnicity and potentially modifiable epidemiologic risk factors. Conclusions and Relevance In this study, population-based estimates of cumulative breast cancer risk for established PVs, as informed by the CARRIERS case-control sample, varied by family history and potentially modifiable risk factors. These estimates provide guidance for identifying individuals who will most benefit from enhanced screening and prevention strategies.
Mitigating Inequities? Or Compromising Patient Privacy and Safety?
Cathcart-Rake, Elizabeth

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 9, 2025 | Volume: 23 | Issue: 10 | Pages: No page available

10.6004/jnccn.2025.7108 | PMID 41067271 Get It

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025
Advani, Ranjana H. , Andreadis, B., Chang, Julie , Christian, Beth , deVos, Sven, Fayad, Luis , Hamid, Muhammad Saad , Hernandez‐Ilizaliturri, Francisco J. , Karimi, Yasmin , King, Rebecca L. , Krivacic, Susan, LaCasce, Ann S. , Messmer, Marcus , Rabinovitch, Rachel , Roberts, Kenneth B. , Saito, Naoyuki G. , Smith, Stephen D. , Swinnen, Lode J., Tuscano, Joseph M. , Dwyer, Mary A., Sundar, Hema, Advani, Ranjana H , Karimi, Yasmin H , Zelenetz, Andrew D. , Gordon, Leo I. , Abramson, Jeremy S. , Bartlett, Nancy L. , Budde, Lihua E. , Caimi, Paolo F. , Dholaria, Bhagirathbhai , Habermann, Thomas M. , Hu, Boyu , Kelsey, Chris R. , Kline, Justin Paul , Landsburg, Daniel J. , Lim, Megan S. , Ramakrishnan, Praveen , Reid, Erin G , Saeed, Hayder , Vose, Julie M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 9, 2025 | Volume: 23 | Issue: 10 | Pages: No page available

10.6004/jnccn.2025.0048 | PMID 41067277 Get It

The treatment landscape of B-cell lymphomas has significantly evolved in recent years with approval of novel targeted therapies. CD3 × CD20 bispecific antibodies and CD19-directed monoclonal antibodies and antibody–drug conjugates have demonstrated efficacy in relapsed/refractory follicular lymphoma (FL). Bruton tyrosine kinase (BTK) inhibitor–based regimens are emerging as effective treatment options for patients with TP53-mutated classical mantle cell lymphoma (MCL). Results from ongoing clinical trials suggest that the addition of CD3 × CD20 bispecific antibodies to chemoimmunotherapy improves outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). These NCCN Guideline Insights highlight significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, MCL, and DLBCL.
Hematopoietic Cell Transplantation, Version 3.2025, NCCN Clinical Practice Guidelines In Oncology
Loren, Alison W. , Bolaños‐Meade, Javier , Brammer, Jonathan E. , Cowden, Meredith , Stasi, Antonio Di , El‐Jawahri, Areej , Elmariah, Hany , Gundabolu, Krishna , Gutman, Jonathan A. , Ho, Vincent T. , Hoeg, Rasmus T. , Horwitz, Mitchell E. , Jamy, Omer , Dabaja, Mohamed Kharfan, Lee, Lauren , Luszcak, Christina, Magenau, John, Martin, Thomas , Mittal, Varun , Moreira, Jonathan , Muffly, Lori , Nakamura, Ryotaro , Nawas, Mariam, Ninos, Cameron , Oliai, Caspian , Pidala, Joseph A. , Randolph, Brion, Tessier, Jeffrey, Topal, Jeffrey , Varshavsky‐Yanovsky, Asya, Jones, Frankie, Stehman, Katie, Elmariah, Hany , Jamy, Omer , Muffly, Lori , Mielcarek, Marco B. , Kassim, Adetola A , Logan, Aaron C , Nawas, Mariam T. , Nieto, Yago , Oliai, Caspian H , Papanicolaou, Genovefa A. , Schroeder, Mark A. , Tzachanis, Dimitrios

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 9, 2025 | Volume: 23 | Issue: 10 | Pages: No page available

10.6004/jnccn.2025.0047 | PMID 41067275 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hematopoietic Cell Transplantation (HCT) provide expert, multidisciplinary recommendations for autologous and allogeneic HCT based on current evidence. The NCCN Guidelines focus on pretransplant recipient evaluation, hematopoietic cell mobilization, conditioning, and the diagnosis and management of graft-versus-host disease (GVHD), a common complication of allogeneic HCT that is associated with significant morbidity. This selection from the NCCN Guidelines for HCT focuses on the diagnosis, workup, and management of acute and chronic GVHD, as well as important supportive care considerations.
Lifestyle Change Interventions: Effectiveness of REWIND, a Virtual, Community‐Based Weight Management Program
Rothberg, Amy E. , Ye, Wen , Miller, Nicole , Rizza, Robert A.

Mayo Clinic

Obesity Science & Practice | October 9, 2025 | Volume: 11 | Issue: 5 | Pages: No page available

10.1002/osp4.70092 | PMID 41079537 Get It

ABSTRACT Importance Despite the current enthusiasm for anti‐obesity medications, there is a critical need for effective lifestyle interventions that can be broadly implemented. Objective To assess the effectiveness of REWIND, an obesity and diabetes treatment program. Design Prospective cohort study. Setting Virtual, community‐based weight management program. Participants Two‐hundred and nineteen participants, BMI ≥ 30 kg/m 2 , with and without type 2 diabetes (T2D). Intervention Three phases: “induction” with meal replacement diet to promote ≥ 15% weight loss; “transition” to everyday foods; and “maintenance” to prevent weight regain. REWIND leveraged teams including community leaders, media personalities, nationally recognized athletes and participants, to disseminate information, and foster belonging, commitment, and resilience. Main Outcomes The co‐primary outcomes were the change in weight at 6‐, 12‐, and 18 months. Secondary outcomes were the proportion of patients achieving ≥ 5%, 10%, 15%, and 20% weight loss at 6, 12, and 18 months, and remission rates in T2D at 6‐, 12‐, and 18‐month, respectively. Results Two hundred and nineteen participants (mean age 49.1 [SD 10.5] years), 37% men, 12% Black, 26% with T2D. Weight decreased from: 114.4 (20.8) kg to 96.1 (18.4) kg at 6 months, to 98.5 (18.1) kg at 12 months, and to 101.1 (20.5) kg at 18 months. Weight loss percentages at 6, 12, and 18 months were ≥ 5%: 95%, 91%, 84%; ≥ 10%: 79%, 72%, 67%; ≥ 15%: 58%, 46%, 47%; and ≥ 20%: 24%, 25%, 22%. Diabetes remission was achieved by 52% and 43% of participants with T2D at 12‐ and 18‐month, respectively. Limitations Single geographic region. Weight was self‐reported. Conclusion A virtual community‐based program for individuals with obesity and T2D facilitated substantial weight loss and T2D remission. This model has the potential for wide‐scale implementation in diverse settings.